MedPath

Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

Pediatric Expanded Access Program-Oral Solution (0831-908)

Phase 3
Completed
Conditions
HIV Infections
First Posted Date
2007-10-15
Last Posted Date
2015-11-30
Lead Sponsor
Merck Sharp & Dohme LLC
Registration Number
NCT00543530

Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001)

Phase 1
Completed
Conditions
Cancer, Neoplasms, Tumors
Interventions
Drug: MK-5108
Drug: docetaxel
First Posted Date
2007-10-15
Last Posted Date
2024-06-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
35
Registration Number
NCT00543387

Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)

Phase 3
Terminated
Conditions
Diabetes Mellitus, Type 2
First Posted Date
2007-10-15
Last Posted Date
2015-06-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
382
Registration Number
NCT00543361

MK0767 and Sulfonylurea Combination Study (0767-027)

Phase 3
Terminated
Conditions
Diabetes Mellitus, Type 2
First Posted Date
2007-10-15
Last Posted Date
2015-06-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
129
Registration Number
NCT00543491

Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

Phase 3
Completed
Conditions
Vaginal Cancer
Vulvar Cancer
Human Papillomavirus Infection
Cervical Cancer
Genital Warts
First Posted Date
2007-10-15
Last Posted Date
2018-11-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
14840
Registration Number
NCT00543543

MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

Phase 2
Completed
Conditions
Diabetes Mellitus, Type 2
Metabolic Syndrome
First Posted Date
2007-10-15
Last Posted Date
2015-05-22
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
154
Registration Number
NCT00543595

Study A - MK0767 Monotherapy Study

Phase 3
Terminated
Conditions
Diabetes Mellitus, Type 2
First Posted Date
2007-10-15
Last Posted Date
2015-02-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
99
Registration Number
NCT00543517

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

Phase 2
Completed
Conditions
Anxiety Disorders
First Posted Date
2007-10-15
Last Posted Date
2015-11-26
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
60
Registration Number
NCT00543920

MK0767 in Type 2 Diabetes (0767-012)

Phase 2
Terminated
Conditions
Type 2 Diabetes Mellitus
First Posted Date
2007-10-15
Last Posted Date
2015-06-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
514
Registration Number
NCT00543556

12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003)

Phase 2
Terminated
Conditions
Arthritis, Rheumatoid
Osteoarthritis
First Posted Date
2007-10-15
Last Posted Date
2015-06-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
49
Registration Number
NCT00543465
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy